Return to homepagePandemic Pact

Pathogen Genomics Dual Utility to Deliver Personalised Medicine and Precision Public Health

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA276612

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2023
    2027

  • Known Financial Commitments (USD)

    $441,364.07

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    University of Sydney

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Novel treatments for COVID-19 have rapidly been developed and are used to prevent severe SARS-CoV-2 infection in patients with underlying health conditions. The SARS-CoV-2 virus is evolving rapidly and this has led to variants that can reduce the effectiveness of novel antiviral treatments. This grant will develop genomic tools to predict the optimal SARS-CoV-2 therapeutic needed whilst monitoring for viral resistance in patients that fail antiviral therapy.